Characterizing the Effects of Platelet-Rich Fibrin (PRF) as a Palatal Wound Dressing on Quality of Life and Sleep Following Mucogingival Surgery. Study Was Conducted at the Air Force Post Graduate Dental School. All HIPPA Consents and Research Informed Consents Are Located at JBSA-Lackland.
4 juin 2026 mis à jour par: David Seiler, 59th Medical Wing
Characterizing the Effects of Leukocyte-Platelet-Rich Fibrin on Sleep and Perceived Quality of Life on Mucogingival Periodontal Surgery Healing. Arm 1: Influence of Platelet-rich Fibrin on Quality of Life Following Mucogingival Surgery: A Randomized Controlled Trial.
The goal of this clinical trial (2-arm) is to determine if the application of platelet rich fibrin (PRF) to palatal donor sites influence patients quality of life, sleep efficiency, and healing following mucogingival surgery. All patients were enrolled in the Air Force Post Graduate Dental School periodontics program and each patient required mucogingival surgery. The main question[s] it aims to answer [is/are]:
- Does the application of PRF to palatal donor sites influence patient's quality of life following mucogingival surgery. [outcome measure 1]
- Does the application of PRF to palatal donor sites influence patient's sleep quality following mucogingival surgery. [outcome measure 2]
- Does the application of PRF to palatal donor sites influence palatal healing following mucogingival surgery. [outcome measure 3] Researchers will compare the application of PRF (test) as a palatal dressing to a commercially available product (control; oxidized cellulose membrane or collagen dressing) to determine the difference of effects.
Participants will be randomly assigned to either receiving PRF or a commercially available product on the day of surgery. A survey response will be conducted at five time points (pre-operative, 24-hours, 72 hours, 1 week, 2 week) to obtain a quality of life metric. Sleep data was collected via a wearable device one week pre-surgical intervention and two weeks postoperatively. Finally, a clinical healing index was performed at 1 and 2 weeks post-operatively to obtain a healing score.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
78
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Texas
-
San Antonio, Texas, États-Unis, 78236
- Air Force Post Graduate Dental School
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- age > 18 or < 99
- required a mucogingival surgery
- had not taken an antibiotic for one month
- planned for a non-emergent periodontal procedure
Exclusion Criteria:
- pregnant or within 6 months post-partum
- female subjects who are nursing
- subjects who are decisionally challenged
- patients who have undergone antibiotic therapy in the past month
- ASA IV or higher status
- patients who have undergone chronic therapy with medications that could affect periodontal status or healing
- incompatible mobile phone devices.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Quality of Life
The Qualtrics survey tool sent out automated emails at 24 hours, 72 hours, 1-week and 2-week time points from the time of pre-surgery survey completion.
Surveys included: (1) OHIP-14 questionnaire, which includes 14 questions related to seven different patient domains; (2) What is your pain at the palatal harvest site on a scale of 0-10?
(NRS-11); and (3) Did you take any mediation today to relieve pain or swelling?
(yes/no).
|
The test group had approximately 40 ml of whole venous blood collected from their antecubital fossa (R/L) prior to surgical start for the fabrication of PRF.
Tubes were placed immediately into a US Food and Drug Administration (FDA)-approved horizontal centrifuge (Horizon 6 Drucker Diagnostics; Port Matilda, PA), and spun at 2300 rpm (700 g) for 16 min.
After the centrifugation was complete, the PRF matrices were compressed into membranes.
At the completion of surgery, PRF membranes (1-3) were used as a wound dressing at the harvest site.
A palatal stent was used to secure the PRF via compression only, and no sutures were utilized for fixation at the harvest sites.
Patients were instructed not to remove the palatal stent for 48 hours.
On the day of surgery, subjects randomized into the control group had a commercially available product of the surgeons choice (collagen matrices or oxidized cellulose membrane) placed at the palatal donor site.
The matrix was compressed with a palatal stent and subjects were instructed to not remove the stent for 48 hours.
|
|
Expérimental: Sleep Quality
After informed consent is obtained at the pre-op appointment, subjects undergoing mucogingival surgery will be given a sleep monitoring device (SleepImage® Ring 2019, SleepImage, Denver, CO) and will complete a baseline QoL (Qualtrics XM®, 2002, Qualtrics, Seattle WA).
The sleep monitoring app will be downloaded on subjects' phones and each subject will be briefed on the function of the application.
Subjects will be instructed to wear the device nightly throughout the study.
The subject will be instructed to complete the same QoL questionnaire at 24 hours, and 72 hours, as well as at the one-week and two-week post-operative appointments.
|
The test group had approximately 40 ml of whole venous blood collected from their antecubital fossa (R/L) prior to surgical start for the fabrication of PRF.
Tubes were placed immediately into a US Food and Drug Administration (FDA)-approved horizontal centrifuge (Horizon 6 Drucker Diagnostics; Port Matilda, PA), and spun at 2300 rpm (700 g) for 16 min.
After the centrifugation was complete, the PRF matrices were compressed into membranes.
At the completion of surgery, PRF membranes (1-3) were used as a wound dressing at the harvest site.
A palatal stent was used to secure the PRF via compression only, and no sutures were utilized for fixation at the harvest sites.
Patients were instructed not to remove the palatal stent for 48 hours.
On the day of surgery, subjects randomized into the control group had a commercially available product of the surgeons choice (collagen matrices or oxidized cellulose membrane) placed at the palatal donor site.
The matrix was compressed with a palatal stent and subjects were instructed to not remove the stent for 48 hours.
|
|
Expérimental: Healing
At 1- and 2- weeks, patients returned for post-operative appointments.
At the follow-up appointment the surgeons were asked to document the presence of suppuration or bleeding at the palatal wound site.
A standardized photograph was then taken with the following parameters (F-stop: 29, ISO: 200, Shutter Speed: 125).
Three calibrated, blinded examiners then assessed the palatal wound based on the Landry et al palatal healing index.
|
The test group had approximately 40 ml of whole venous blood collected from their antecubital fossa (R/L) prior to surgical start for the fabrication of PRF.
Tubes were placed immediately into a US Food and Drug Administration (FDA)-approved horizontal centrifuge (Horizon 6 Drucker Diagnostics; Port Matilda, PA), and spun at 2300 rpm (700 g) for 16 min.
After the centrifugation was complete, the PRF matrices were compressed into membranes.
At the completion of surgery, PRF membranes (1-3) were used as a wound dressing at the harvest site.
A palatal stent was used to secure the PRF via compression only, and no sutures were utilized for fixation at the harvest sites.
Patients were instructed not to remove the palatal stent for 48 hours.
On the day of surgery, subjects randomized into the control group had a commercially available product of the surgeons choice (collagen matrices or oxidized cellulose membrane) placed at the palatal donor site.
The matrix was compressed with a palatal stent and subjects were instructed to not remove the stent for 48 hours.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quality of Life: OHIP-14 summative scores utilized as a quality of life metric at five different time points. These scores were compared between the test and control group.
Délai: Pre-surgical survey to 2 weeks following surgical intervention.
|
The Qualtrics survey tool sent out automated emails at 24 hours, 72 hours, 1-week and 2-week time points from the time of pre-surgery survey completion. Surveys included: (1) OHIP-14 questionnaire, which includes 14 questions related to seven different patient domains; (2) What is your pain at the palatal harvest site on a scale of 0-10? (NRS-11); and (3) Did you take any mediation today to relieve pain or swelling? (yes/no). The additive OHIP-14 score served as the primary outcome variable. The quality of life survey was completed pre-surgically, 24 hours, 72 hours, 1 week, and 2 weeks. |
Pre-surgical survey to 2 weeks following surgical intervention.
|
|
Sleep Quality: sleep efficiency index obtained from wearable device.
Délai: 1 week pre-surgery to 2-weeks following surgical intervention.
|
A sleep monitoring device was issued to patients following informed consent (SleepImage® Ring 2019, SleepImage, Denver, CO).
The sleep monitoring app will be downloaded on subjects' phones and each subject will be briefed on the function of the application.
Subjects will be instructed to wear the device nightly throughout the study.
|
1 week pre-surgery to 2-weeks following surgical intervention.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pain: a numeric pain scale (0-10) was used to document site specific palatal harvest pain.
Délai: From pre-surgery survey, final survey was 2 weeks post surgical intervention.
|
The Qualtrics survey tool sent out automated emails at 24 hours, 72 hours, 1-week and 2-week time points from the time of pre-surgery survey completion.
Survey question: What is your pain at the palatal harvest site on a scale of 0-10?
(NRS-11)
|
From pre-surgery survey, final survey was 2 weeks post surgical intervention.
|
|
Analgesic Consumption: a survey tool was used to document patients medication use post-surgery.
Délai: From pre-surgery survey to two weeks post surgical intervention.
|
The Qualtrics survey tool sent out automated emails at 24 hours, 72 hours, 1-week and 2-week time points from the time of pre-surgery survey completion.
Survey question: Did you take any mediation today to relieve pain or swelling?
(yes/no).
|
From pre-surgery survey to two weeks post surgical intervention.
|
|
Physiologic Healing at Palatal Donor Site: 5-point healing scale
Délai: Healing was assessed at 1-week and 2-weeks post surgical intervention.
|
At the follow-up appointment the surgeons were asked to document the presence of suppuration or bleeding at the palatal wound site.
A standardized photograph was then taken with the following parameters (F-stop: 29, ISO: 200, Shutter Speed: 125).
Three calibrated, blinded examiners then assessed the palatal wound based on the Landry et al palatal healing index.
|
Healing was assessed at 1-week and 2-weeks post surgical intervention.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
24 mai 2024
Achèvement primaire (Réel)
18 mars 2025
Achèvement de l'étude (Réel)
18 mars 2025
Dates d'inscription aux études
Première soumission
26 mai 2026
Première soumission répondant aux critères de contrôle qualité
4 juin 2026
Première publication (Réel)
10 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
10 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
4 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- FWH2024005H
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
All de-identified participant date sets are to be shared upon request.
Délai de partage IPD
Beginning 3 months and ending 3 years after the publication of results.
Critères d'accès au partage IPD
The Air Force Post Graduate Dental School will be in charge of allowing access to IPD upon request.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .